Sandoz

The Sandoz plant in Kundl is the last fully integrated penicillin factory in Europe, but it is threatened with closure because of significantly cheaper Chinese competition and high energy and production costs. Despite EU funding to expand capacity, production is economically unviable according to Sandoz, which has therefore filed an anti-dumping investigation in Brussels against Chinese active ingredients. Closing the facility would massively increase Europe’s dependence on China for vital antibiotics and endanger supply security. » More on n-tv.de

Had 10,000 CHF been invested in Sandoz shares on 13 October 2025 (closing price 48.99 CHF), the value on 13 October 2026 would be 14,623.39 CHF (closing price 71.64 CHF), i.e. 46.23 percent higher. The calculation does not take stock splits or dividends into account. Sandoz's stock made its market debut on 4 October 2023 at an initial price of 24.00 CHF. » More on finanzen.net

US states have asked a federal court in Connecticut for preliminary approval of a settlement with Sandoz over alleged price‑fixing for generics. The agreement covers 43 US jurisdictions and provides for total payments of $400 million over seven years, about $320.6 million as settlement principal and $79.4 million in interest. Sandoz and Fougera Pharmaceuticals, a subsidiary acquired in 2012, are accused of fixing prices and dividing markets; Sandoz denies the allegations. The first payment is due after final court approval, and no decision date has yet been set. » More on finanzen.net